01
What changed in biotechnology regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
Capricor Therapeutics received authorization from the FDA to file an amendment to its approval application for a Duchenne muscular dystrophy cell therapy.
Read at fiercebiotech.com ↗03
The European Medicines Agency (EMA) has officially accepted the marketing authorization application for VLA15, a Lyme disease vaccine candidate developed by Pfizer and Valneva.
Read at citeline.com ↗04
Government funding initiatives for biotechnology hubs are expanding across regions including Pennsylvania and Kansas City as of August 2026.
Read at biopharmadive.com ↗What funding rounds and acquisitions happened in biotechnology this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
05
Skye Bioscience and Redx Pharma have entered into an agreement to merge their operations to form a new public company named Fibrx Therapeutics.
Read at fiercebiotech.com ↗What products launched in biotechnology this week?
Notable product launches, releases and platform updates from the week.
06
Molendotech, a University of Plymouth spinout, plans to launch a water quality mapping app in the UK and US in October 2026.
Read at theguardian.com ↗07
Bristol Myers Squibb (BMS) received regulatory approval for Zenbexus on August 14, 2026.
Read at citeline.com ↗08
Louis Dreyfus Company (LDC) has opened a large-scale pea protein processing facility in Yorkton, Saskatchewan, Canada, in July 2026.
Read at foodnavigator.com ↗09
French neurotechnology startup Robeauté is developing rice-sized microrobots designed for precise drug delivery into the brain.
Read at bloomberg.com ↗10
The US Food and Drug Administration (FDA) granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adult patients with relapsed or refractory multiple myeloma.
Read at pharmexec.com ↗11
On August 14, 2026, the newly public biotechnology company Yarrow announced a first-in-class therapeutic approach targeting Graves' disease and Thyroid Eye Disease (TED).
Read at citeline.com ↗12
The FDA granted accelerated approval to Bristol Myers Squibb's drug Zenbexus (iberdomide) for the treatment of adults with relapsed or refractory multiple myeloma.
Read at medcitynews.com ↗What financial results were reported in biotechnology this week?
Earnings, guidance and other financial results reported this week.
13
WuXi AppTec Co. has seen its stock price rally by 100% despite being designated as a Chinese military company by the Pentagon.
Read at bloomberg.com ↗14
Vogenx, a biotechnology company based in Raleigh, North Carolina, raised $81 million in its initial public offering on the Nasdaq exchange.
Read at medcitynews.com ↗What research was published in biotechnology this week?
New research findings and studies published this week.
15
A new report from the Milken Institute identifies coverage and reimbursement strategies as a critical barrier for women's health startups.
Read at medcitynews.com ↗16
Researchers have discovered that mice retain access to memories after emerging from hibernation, a state characterized by a significant reduction in brain activity and synaptic connections.
Read at 404media.co ↗17
Researchers at the Whitehead Institute, led by Ankur Jain, Whitney Henry, and Pushkal Sharma, discovered that polyamines act as storage molecules for iron to prevent cellular damage.
Read at genengnews.com ↗18
Erin McNulty, a 45-year-old struggling with long-term methamphetamine addiction, underwent a noninvasive focused ultrasound procedure at West Virginia University in 2024.
Read at wired.com ↗What people moved in and out of biotechnology roles this week?
Executive appointments and departures reported this week.
19
Ying Huang, the former CEO of Legend Biotech, has been appointed as the new leader of K2 Therapeutics.
Read at fiercebiotech.com ↗20
BioNTech has appointed Guido Oelkers as its new CEO to lead the company's strategic shift toward oncology.
Read at pharmavoice.com ↗What else happened in biotechnology this week?
Developments from the week that fit none of the other sections.
21
BioCryst Pharmaceuticals CEO Charlie Gayer announced that the company is discontinuing its internal drug discovery efforts.
Read at fiercebiotech.com ↗22
Tony Hickson, Chief Business Officer of Cancer Research Horizons, discusses the organization's mission to develop new childhood cancer treatments through the C-Further initiative.
Read at labiotech.eu ↗23
The pharmaceutical and biotechnology sectors are seeing over $16 billion in capital investments across the United States, including major projects by AstraZeneca, Merck, and Eli Lilly in Virginia and Pennsylvania.
Read at genengnews.com ↗24
Labiotech published the results of its 2026 reader survey, which gathered feedback from newsletter subscribers globally.
Read at labiotech.eu ↗25
MapLight Therapeutics is prioritizing its phase 3-ready schizophrenia drug following mixed clinical trial results reported in July 2026.
Read at fiercebiotech.com ↗26
Zealand Pharma CEO Adam Steensberg discussed the growth prospects of the company's weight loss drug candidate, petrelintide, on August 14, 2026.
Read at citeline.com ↗27
Bristol Myers Squibb announced the selection of Houston, Texas, for a new $2.3 billion multi-modal manufacturing campus.
Read at genengnews.com ↗7 of 8 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.